PCA
APLS

Pallas Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Pallas Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,885
Closed -$349K – 870
2025
Q4 		$349K Sell
13,885
-19,192
-58% -$450K 0.01% 643
2025
Q3 		$749K Sell
33,077
-21,772
-40% -$508K 0.03% 410
2025
Q2 		$949K Buy
54,849
+12,315
+29% +$228K 0.04% 345
2025
Q1 		$930K Buy
42,534
+29,165
+218% +$806K 0.04% 311
2024
Q4 		$427K Sell
13,369
-554
-4% -$16.7K 0.02% 398
2024
Q3 		$384K Buy
+13,923
New +$516K 0.02% 409

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pallas Capital Advisors's APLS Position: Q1 2026 in Review

Pallas Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 13,885 shares — an estimated $349K sold.

Pallas Capital Advisors first reported a position in APLS in Q3 2024 and held it in 6 quarters. The position peaked at $949K in Q2 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Pallas Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 13,885 Apellis Pharmaceuticals shares in Q1 2026, an estimated $349K.
  • Pallas Capital Advisors first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Pallas Capital Advisors's Apellis Pharmaceuticals position peaked at $949K in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.